CytomX Therapeutics to Announce Third Quarter 2016 Financial Results
2016年10月27日 - 9:00PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, will announce financial results for the third
quarter, ended September 30, 2016, and provide an update on
November 3, 2016, after the NASDAQ market close.
The company will not conduct a conference call in conjunction
with this financial results press release.
About CytomX TherapeuticsCytomX is an
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody
technology platform. The company uses the platform to create
proprietary cancer immunotherapies against clinically-validated
targets, as well as to develop first-in-class investigational
cancer therapeutics against novel targets. CytomX believes that its
Probody platform has the potential to improve the combined efficacy
and safety profile of monoclonal antibody modalities, including
cancer immunotherapies, antibody drug conjugates and
T-cell-recruiting bispecific antibodies. Probody therapeutics are
designed to take advantage of unique conditions in the tumor
microenvironment to enhance the tumor-targeting features of an
antibody and reduce drug activity in healthy tissues. The
company’s investigational Probody therapeutics address
clinically-validated cancer targets in immuno-oncology, such as
PD-L1, against which the clinical candidate CX-072 is directed, as
well as novel targets, such as CD-166, that are difficult to drug
without causing damage to healthy tissues. In addition to its
proprietary programs, CytomX is collaborating with strategic
partners including AbbVie, Bristol-Myers Squibb Company, Pfizer
Inc., MD Anderson Cancer Center, and ImmunoGen, Inc. For more
information, visit www.cytomx.com.
Forward-Looking StatementsThis press release
includes forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors that are difficult to predict, may be beyond our
control, and may cause the actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied in such
statements. Accordingly, you should not rely on any of these
forward-looking statements. Our Probody platform is in preclinical
development, and the process by which a preclinical technology
could potentially lead to an approved product is long and subject
to significant risks and uncertainties. Applicable risks and
uncertainties include those relating to our preclinical research
and development and other risks identified under the heading "Risk
Factors" included in our filings with the SEC. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Corporate Communications Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024